Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$73.65 ▲ +0.36
(+0.49%)
MKT CAP: $1.08B • VOL: 358.8K
52W L $57 52W H $155
INBX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.3M | $200.0K | $1.8M |
| YoY Revenue Growth % | +550.0% | -88.9% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$135.0M | -$331.4M | -$219.2M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$140.1M | $1.69B | -$241.4M |
| EBITDA (Normalized) | -$135.0M | -$329.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$129.8M | -$194.4M | -$193.3M |
| Capital Expenditures (CapEx) | $31.0K | $2.6M | — |
| Free Cash Flow (FCF) | -$129.8M | -$197.0M | -$193.3M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $124.2M | $152.6M | — |
| Total Debt (Short + Long Term) | $100.6M | $0 | — |
| Total Stockholders' Equity | $8.0M | $133.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR INBX.